Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.90 [0.57, 1.43] | | < 1 | | 86% | 2 studies (2/-) | 67.1 % | low | not evaluable | high | crucial | - |
deaths (OS) (extension) | 0.73 [0.64, 0.83] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
MFS | 1.01 [0.57, 1.80] | | < 1 | | 92% | 2 studies (2/-) | 48.5 % | low | not evaluable | high | important | - |
MFS (extension) | 0.76 [0.64, 0.90] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
RFS (extension) | 1.03 [0.55, 1.90] | | < 1 | | 96% | 2 studies (2/-) | 46.7 % | low | not evaluable | high | important | - |
RFS/DFS | 1.07 [0.53, 2.16] | | < 1 | | 96% | 2 studies (2/-) | 42.7 % | low | not evaluable | high | important | - |
safety endpoints 00 |
AE (any grade) | 3.95 [1.10, 14.25] | | < 1 | | 76% | 2 studies (2/-) | 1.8 % | low | not evaluable | high | non important | - |
AE (grade 3-4) | 0.64 [0.02, 18.93] | | < 1 | | 100% | 2 studies (2/-) | 59.9 % | low | not evaluable | high | non important | - |
TRAE (any grade) | 7.68 [2.18, 27.11] | | < 1 | | 94% | 2 studies (2/-) | 0.1 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) | 11.09 [2.29, 53.68] | | < 1 | | 96% | 2 studies (2/-) | 0.1 % | low | not evaluable | high | non important | - |
TRAE leading to death (grade 5) | 6.57 [0.79, 54.87] | | < 1 | | 0% | 2 studies (2/-) | 4.2 % | low | not evaluable | high | non important | - |
TRAE leading to discontinuation (any grade) | 13.38 [5.44, 32.86] | | < 1 | | 89% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
Colitis TRAE (grade 3-4) | 39.14 [5.34, 286.74] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 11.43 [3.15, 41.55] | | < 1 | | 61% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
Endocrine disorders TRAE (grade 3-4) | 42.70 [5.84, 312.15] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Gastrointestinal disorders TRAE (grade 3-4) | 13.77 [6.25, 30.34] | | < 1 | | 41% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
Hepatobiliary disorders TRAE (grade 3-4) | 16.04 [2.04, 126.16] | | < 1 | | 74% | 2 studies (2/-) | 0.4 % | low | not evaluable | high | non important | - |
Hypophysitis TRAE (grade 3-4) | 11.06 [1.65, 74.15] | | < 1 | | 38% | 2 studies (2/-) | 0.7 % | low | not evaluable | high | non important | - |
Nervous system disorders TRAE (grade 3-4) | 18.45 [1.07, 319.15] | | < 1 | | 0% | 1 study (1/-) | 2.4 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 3.28 [1.24, 8.67] | | < 1 | | 0% | 2 studies (2/-) | 0.8 % | low | not evaluable | high | non important | - |
Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 9.81 [1.70, 56.53] | | < 1 | | 43% | 2 studies (2/-) | 0.5 % | low | not evaluable | high | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 0.04 [0.01, 0.17] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Colitis AE (grade 3-4) | 6.26 [2.61, 15.03] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.01 [0.00, 0.15] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.06 [0.01, 0.46] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 0.26 [0.18, 0.37] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.05 [0.03, 0.10] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 0.04 [0.01, 0.11] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Hypophysitis AE (grade 3-4) | 11.01 [2.57, 47.24] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
Hypothyroidism AE (grade 3-4) | 0.14 [0.02, 1.16] | | < 1 | | 0% | 1 study (1/-) | 96.5 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 0.80 [0.45, 1.45] | | < 1 | | 0% | 1 study (1/-) | 76.6 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 0.97 [0.55, 1.70] | | < 1 | | 0% | 1 study (1/-) | 54.8 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.01 [0.00, 0.07] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.14 [0.07, 0.26] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 0.21 [0.08, 0.56] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 0.06 [0.03, 0.15] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.07 [0.02, 0.29] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 0.02 [0.00, 0.16] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |